Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | Chief Medical Officer | February 01, 2017 | February 09, 2017 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Chief Medical Officer | October 28, 2019 | October 30, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date February 01, 2017 · Filed February 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2027-01-30 | Direct | 165,000 |
Reported balance
After 2017-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-30 · Grant · Acquired 165,000 · Balance 165,000 F1: The option was granted on 1/30/17 contingent upon the Reporting Person commencing employment on 2/1/17. F2: The option vests based on certain performance milestones. The option will be forfeited if such milestones are not met by certain dates. |
| Stock Option (Right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2027-01-30 | Direct | 185,000 |
Reported balance
After 2017-01-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-30 · Grant · Acquired 185,000 · Balance 185,000 F1: The option was granted on 1/30/17 contingent upon the Reporting Person commencing employment on 2/1/17. F3: The option vests in four equal annual installments beginning on the first anniversary of the vesting commencement date, 2/1/18, subject to continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on 1/30/17 contingent upon the Reporting Person commencing employment on 2/1/17.
F2: The option vests based on certain performance milestones. The option will be forfeited if such milestones are not met by certain dates.
F3: The option vests in four equal annual installments beginning on the first anniversary of the vesting commencement date, 2/1/18, subject to continued employment.
Editas Medicine, Inc.
Report date October 28, 2019 · Filed October 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2019-10-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-10-28 · Grant · Acquired 25,000 · Balance 25,000 F1: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on October 28, 2020 continuing through October 28, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.61 · Expires 2029-10-27 | Direct | 150,000 |
Reported balance
After 2019-10-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-28 · Grant · Acquired 150,000 · Balance 150,000 F2: This option was granted on October 28, 2019 and is scheduled to vest over four years, with 25% of the shares to vest on October 28, 2020 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on October 28, 2020 continuing through October 28, 2023.
F2: This option was granted on October 28, 2019 and is scheduled to vest over four years, with 25% of the shares to vest on October 28, 2020 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2019 Filed Oct 30, 2019 20:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $21.61 | $0.00 |
DisclosureSEC source: 0001179110-19-011289 · edgar.xml · derivative · entry 2 Abrams Judith R · CIK 0001697499 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-10-27 F2 · derivative.exercise_date: This option was granted on October 28, 2019 and is scheduled to vest over four years, with 25% of the shares to vest on October 28, 2020 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 28, 2023. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 20:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-011289 · edgar.xml · nonDerivative · entry 1 Abrams Judith R · CIK 0001697499 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on October 28, 2020 continuing through October 28, 2023. Read SEC document |
| January 30, 2017 Filed Feb 9, 2017 21:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to buy Common Stock) · Derivative | 185,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001354488-17-000245 · issuerdirect_section16.xml · derivative · entry 2 Abrams Judith R · CIK 0001697499 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2027-01-30 F1 · date: The option was granted on 1/30/17 contingent upon the Reporting Person commencing employment on 2/1/17. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on the first anniversary of the vesting commencement date, 2/1/18, subject to continued employment. Read SEC document |
| January 30, 2017 Filed Feb 9, 2017 21:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to buy Common Stock) · Derivative | 165,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001354488-17-000245 · issuerdirect_section16.xml · derivative · entry 1 Abrams Judith R · CIK 0001697499 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2027-01-30 F1 · date: The option was granted on 1/30/17 contingent upon the Reporting Person commencing employment on 2/1/17. F2 · derivative.exercise_date: The option vests based on certain performance milestones. The option will be forfeited if such milestones are not met by certain dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.